Salix Pharmaceuticals, Ltd. Release: FDA Ad Comm Provides Recommendations Regarding The Potential Cardiovascular Risk Associated With The Class Of Peripherally-Active Opioid Receptor Antagonists And The Trials To Support Approval Of Products For OIC RALEIGH, N.C. & TARRYTOWN, N.Y.-- --Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals today ... (more)
http://ift.tt/1qGDx74
http://ift.tt/1qGDx74
No comments:
Post a Comment